Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupNeuro-OncologyradiotherapyDiseaseMedulloblastomaSubgroupICD10C71.-C71.6MeSHMedulloblastomaSequenceChemotherapyChemo-substanceCisplatinLomustineVincristineChemo-substanceCisplatinLomustineVincristineChemo-substanceCisplatinLomustineVincristineChemo-substanceCisplatinLomustineVincristineNo. Substances3 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances8Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseMaintenanceTherapy intentioncurativeRisksEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeuropathyNeutropeniaOtotoxicity only studiesPublicationAuthorKortmann RDiseaseMedulloblastom im Kindesalter, Alter 3-18OriginDepartment of Radiotherapy University of Tübingen, HIT 91 / HIT 2000 trial / HIT-MED study centerProtocols in Revision 1 protocol foundProtocols under revision.Lomustine 75 / Vincristine 1.5 / Cisplatin 70, Medulloblastoma, maintenance. (PID915 V1.1)
